|
|
Post by JHam on Nov 3, 2014 14:59:39 GMT
|
|
|
|
Post by hoosier57 on Oct 17, 2015 22:57:42 GMT
Yes I am in this one. Nov 13,2014 Dr Scarlett announced a collaborative effort with Janssen pharmaceutical.Janssen is in charge of development of Geron's imetelstat.
|
|
|
|
Post by hoosier57 on Oct 18, 2015 14:52:26 GMT
I understand that I am to post on mish mash so that it does not appear that I would be guilty of a pump and dump. I will post here because it is what I am posting about and any one acting, it is on them, not me,for their own due diligence. I have failed miserably with the shotgun approach to biotech investing, so I thought I would try investing in the partnerships of big pharma, ( specifically Janssen). I missed on the ride with Pharmacyclics and Genmab. I watched as Pharmacyclics ran from $11 to $262 and Abbvie bought them out in the bidding cycle with JNJ. What really peaked my interest was an article that I read in WSJ by Jonathan Rockoff, appearing March 9, 2014.
|
|
|
|
Post by hoosier57 on Oct 18, 2015 17:13:09 GMT
In the article by Rockoff he refers to a paradigm shift in the philosphy of the way Janssen was conducting business in looking for new therapies in their core competencies. Prior to this shift in business, big pharma would look to develope organically, spending lots of R&D dollars and only delivering on about one third of new therapies to market. Rockoff describes assembling a new drug scout team...this "team" would constantly assess new talent ( new therapies) and assign points to them and also assess from those points the probability of being approved as a new marketable therapy. Much the sames as baseball scouts look for new major league talent.
|
|
|
|
Post by hoosier57 on Oct 18, 2015 19:33:05 GMT
Rockoff points to the part of the scout team, a mew member, Dr Peter Lebowitz. I believe Janssen hired Dr Lebowitz from GSK. Shortly after Dr. Lebowitz was hired, he flew out to California and met with representatives from Pharmacyclics, concerning their new compound Imbruvica/ibrutnibib. Negotiation ensued, perhaps with a little smoozing and Janssen inked a deal with Pharmacyclics. Janssen was chosen over competition of Novartis.
|
|
|
|
Post by hoosier57 on Oct 18, 2015 20:05:01 GMT
Rockoff does a wonderful story-line in revealing the transformation @ Janssen. It is a great read and I have revisited the story many times to reaffirm my reasoning to invest along with Janssen partnerships. During the pharmaceutical presentation of May 20, 2015 by JNJ and their representatives, it was revealed that in a biotech industry survey, Janssen was a partner of choice by approximately 60 percent of the survey responders. In 2013, half the the new therapies being worked on by Janssen were partnerships or collaborative agreements with other companys in development of new therapies. I believe this is the underlying reason Janssen has grown so fast, especially in the field of oncology. What also moved me initially during that presentation by JNJ was that the batting average of getting new therapies to market by Janssen was around 65%, that is twice the average of the industry of getting new therapies through trials and to the market. I also believe Janssen is an industry leader in getting new therapies expedited through the clinical trials and the FDA approval @ slightly over 30 months. An absolute must in doing any DD with JNJ or Janssen is a listen to the four hour presentation of pharmaceutical of the May 20 presentation on the Investor relations page of JNJ.
|
|
|
|
Post by hoosier57 on Oct 22, 2015 17:17:34 GMT
|
|
|
|
Post by JHam on Oct 22, 2015 17:46:44 GMT
Thanks for the link. How is GERN's current cash position? Any need for financing in the near term? |
|
|
|
Post by hoosier57 on Oct 22, 2015 19:44:44 GMT
Sitting on approximately 150 million right now and due to receive 35 million milestone payment from Janssen on this quarters report. The entire clinical trials are a shared cost between Geron and JNJ. The total deal should JNJ opt in will be worth 965 million for Geron which should be way more than enough for the shared cost of trials. This is an all or nothing for Geron...no additional pipeline.Lab is closed. 23 people on the payroll. Scarlett cut everything to the bare bones. Imetelstat is absolutely everything and I do mean everything for the future of Geron. Geron receives some royalties for the stem cell business they sold, but everything else is riding on the patents they have for telomorase inhibition.Dr Peter Lebowitz called Imetelstat "transformational". Dr Tefferri described it as "tantamount to a cure". Lebowitz was instrumental on Pharmacyclics, and my belief his is very much a part of the pursuit of Geron's imetelstat. Janssen has already committed to the clinical trial in MDS for this quarter, this is in addition to the IMBARK study ongoing now for MF. Tefferri will speak at ASH and reveal the results of MDS on nine patients. If it was not going to be good...there is no way Janssen would be proceeding with the additional clinical trial. Please if nothing else you possibly do..please go to the Investor relations page of JNJ go to the May 20 pharmaceutical presentation, segmentize the presentation, go to the oncology portion in which Dr Peter Lebowitz is showing the slides of future therapies that Janssen is working on. On one of the presentation slides is three depictions of bone marrow..normal, diseased with MF, and post treatment with imetelstat. Phenomenal.
|
|
|
|
Post by JHam on Oct 22, 2015 20:00:56 GMT
Sitting on approximately 150 million right now and due to receive 35 million milestone payment from Janssen on this quarters report. The entire clinical trials are a shared cost between Geron and JNJ. The total deal should JNJ opt in will be worth 965 million for Geron which should be way more than enough for the shared cost of trials. This is an all or nothing for Geron...no additional pipeline.Lab is closed. 23 people on the payroll. Scarlett cut everything to the bare bones. Imetelstat is absolutely everything and I do mean everything for the future of Geron. Geron receives some royalties for the stem cell business they sold, but everything else is riding on the patents they have for telomorase inhibition.Dr Peter Lebowitz called Imetelstat "transformational". Dr Tefferri described it as "tantamount to a cure". Lebowitz was instrumental on Pharmacyclics, and my belief his is very much a part of the pursuit of Geron's imetelstat. Janssen has already committed to the clinical trial in MDS for this quarter, this is in addition to the IMBARK study ongoing now for MF. Tefferri will speak at ASH and reveal the results of MDS on nine patients. If it was not going to be good...there is no way Janssen would be proceeding with the additional clinical trial. Please if nothing else you possibly do..please go to the Investor relations page of JNJ go to the May 20 pharmaceutical presentation, segmentize the presentation, go to the oncology portion in which Dr Peter Lebowitz is showing the slides of future therapies that Janssen is working on. On one of the presentation slides is three depictions of bone marrow..normal, diseased with MF, and post treatment with imetelstat. Phenomenal. Thanks! |
|
|
|
Post by hoosier57 on Oct 26, 2015 13:27:34 GMT
ASH abstracts are due to be released 11.05.2015. Dr Tefferri will be presenting data on 9 MDS patients the first week of December. The abstracts may be viewed @ www.hematology.org/Annual-Meeting/Say GERONIMO... |
|
|
|
Post by Whidbeygal CM 20/20 on Nov 30, 2015 19:57:14 GMT
It looks like it is the time for GERN to get recognition. I added today @ 5.06
|
|
|
|
Post by phoenix200k on Dec 2, 2015 22:09:42 GMT
I sold the remaining 950/7950 shares of ocata today and turning my interest again to gern. Catching up on the imeltast trials and bought 1000 shares yesterday at 5.01. I understand this will take another 24 months to commercialize but they still have BTS and 135 million dollars from Johnson & johnson.
|
|
|
|
Post by Whidbeygal CM 20/20 on Dec 7, 2015 16:33:29 GMT
I sold the remaining 950/7950 shares of ocata today and turning my interest again to gern. Catching up on the imeltast trials and bought 1000 shares yesterday at 5.01. I understand this will take another 24 months to commercialize but they still have BTS and 135 million dollars from Johnson & johnson. I added to full position (plus some trading shares) today @ 4.92. Upgrade to price target $10.00 |
|
|
|
Post by phoenix200k on Dec 8, 2015 12:09:17 GMT
Geron was given a $10 outperform rating by piper jaffrey yesterday which would be a 100% premium from where it is today.
This is eerily similar to ocatàs upgrade about 6 months ago (Definitely suffering from ocata ptsd). I guess they're gonna start shorting the hell out of this to 2.50 and then when all seems bleak, the buyout happens for $9 a share.
|
|
|
|
Post by hoosier57 on Dec 21, 2015 13:24:16 GMT
The ongoing clinical trials for Imetelstat are structured for expedited approval just as Janssen did with imbruvica for Pharmacyclics and daratumumab for Genmab.Janssen has plans for NDA in 2017 for secondary treatment in MF.With MDS trial now up and also running, I look for the AML trial to be started 2016.
|
|
|
|
Post by hoosier57 on Dec 21, 2015 19:17:15 GMT
Also I do not forsee a buyout.... Janssen has a good deal with Geron. There will not be a need for an early buyout atleast for the preliminary three trials, but what may be a game changer will be any additional indications that Janssen may start in the future as in certain combo studies.This has become the norm of doing business for Janssen, finding a collaborative therapy, inking a deal, and percentage of future earnings all this for an initial investment of less than one billion dollars.
|
|
|
|
Post by hoosier57 on Dec 21, 2015 23:59:53 GMT
Geron's has a new patent,http://www.freshpatents.com/-dt20151217ptan20150359883.php. This will be for combo therapies. We are just beginning to see the ongoing potential of Geron and what Chip identified for the first time Imetelstat as a platform drug. As Chip said in a previous cc...Imetelstat is bigger than all of us.
|
|
|
|
Post by hoosier57 on Jan 18, 2016 21:52:50 GMT
|
|
|
|
Post by hoosier57 on Sept 11, 2016 22:51:09 GMT
|
|
